{"url_path":"/sec/mist/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059780-index.html","accession_number":"0001104659-26-059780","cik":"0001408443","ticker":"MIST","issuer_name":"Milestone Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059780-index.html","primary_entity_key":"0001408443","primary_entity_name":"Milestone Pharmaceuticals Inc."},"word_count":129,"has_tables":true,"body_markdown":"**Item 2.02.**\n**Results of Operations and Financial Condition.**\n\n \n\nOn May 13, 2026, Milestone Pharmaceuticals Inc.\nissued a press release announcing its financial results for the first quarter ended March 31, 2026 and other business highlights. A copy\nof the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.\n\n \n\nThe information provided in this Item 2.02, including\nExhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended\n(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference\nin any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in\nsuch filing."}